Collections of free desk calendars, issued annually from local businesses, tell the stories of Broome history.

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

For many of us, there’s no avoiding the workday, but making your desk space feel warm and true to your personality can ...

Citi head of US equity strategy Scott Chronert joins Market Domination hosts Julie Hyman and Josh Lipton to discuss Monday's "Magnificent Seven" rally in the context of the recent tech trade ...

The Trade Desk has long been one of the most consistent businesses on the stock market, which merits looking past the shortcomings in its latest quarterly financial report. The company's valuation ...